Smithbridge Asset Management Inc. DE Reduces Position in AbbVie Inc. $ABBV

Smithbridge Asset Management Inc. DE trimmed its stake in AbbVie Inc. (NYSE:ABBV) by 46.5% in the first quarter, HoldingsChannel.com reports. The fund owned 31,584 shares of the company’s stock after selling 27,428 shares during the quarter. Smithbridge Asset Management Inc. DE’s holdings in AbbVie were worth $6,869,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also made changes to their positions in the company. Norges Bank purchased a new stake in AbbVie during the 4th quarter worth about $5,865,055,000. Wellington Management Group LLP lifted its holdings in AbbVie by 457.4% in the 3rd quarter. Wellington Management Group LLP now owns 10,536,901 shares of the company’s stock valued at $2,439,714,000 after purchasing an additional 8,646,424 shares in the last quarter. Capital World Investors boosted its stake in shares of AbbVie by 106.3% during the 4th quarter. Capital World Investors now owns 13,071,444 shares of the company’s stock worth $2,986,777,000 after purchasing an additional 6,736,161 shares during the last quarter. Cardano Risk Management B.V. boosted its stake in shares of AbbVie by 914.6% during the 4th quarter. Cardano Risk Management B.V. now owns 5,444,930 shares of the company’s stock worth $1,244,112,000 after purchasing an additional 4,908,260 shares during the last quarter. Finally, Geode Capital Management LLC grew its holdings in shares of AbbVie by 10.4% during the fourth quarter. Geode Capital Management LLC now owns 44,629,980 shares of the company’s stock worth $10,179,099,000 after buying an additional 4,190,487 shares in the last quarter. 70.23% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of equities analysts have recently weighed in on the stock. William Blair reissued an “outperform” rating on shares of AbbVie in a research report on Monday, March 9th. Wall Street Zen raised shares of AbbVie from a “buy” rating to a “strong-buy” rating in a research note on Saturday, June 27th. DZ Bank upgraded AbbVie from a “hold” rating to a “strong-buy” rating in a report on Thursday, April 30th. Guggenheim reissued a “buy” rating and set a $249.00 price target on shares of AbbVie in a research note on Friday, May 1st. Finally, Weiss Ratings reissued a “hold (c)” rating on shares of AbbVie in a research note on Monday, June 8th. Three research analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and six have given a Hold rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $253.81.

AbbVie Stock Performance

Shares of NYSE:ABBV opened at $251.07 on Thursday. The stock has a 50-day simple moving average of $217.86 and a 200-day simple moving average of $219.76. The stock has a market capitalization of $443.59 billion, a P/E ratio of 123.68, a PEG ratio of 0.83 and a beta of 0.32. AbbVie Inc. has a 1 year low of $184.63 and a 1 year high of $255.99.

AbbVie (NYSE:ABBV) last posted its quarterly earnings results on Wednesday, April 29th. The company reported $2.65 EPS for the quarter, beating the consensus estimate of $2.59 by $0.06. The firm had revenue of $15 billion for the quarter, compared to analyst estimates of $14.72 billion. AbbVie had a net margin of 5.79% and a negative return on equity of 576.45%. AbbVie’s revenue for the quarter was up 12.4% compared to the same quarter last year. During the same quarter last year, the firm posted $2.46 earnings per share. Analysts predict that AbbVie Inc. will post 14.28 earnings per share for the current year.

AbbVie Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, August 14th. Stockholders of record on Wednesday, July 15th will be paid a $1.73 dividend. This represents a $6.92 dividend on an annualized basis and a dividend yield of 2.8%. The ex-dividend date of this dividend is Wednesday, July 15th. AbbVie’s dividend payout ratio (DPR) is currently 340.89%.

AbbVie News Roundup

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: AbbVie reported encouraging Phase 3 data for its venetoclax-based CLL treatment at the EHA 2026 Congress, reinforcing the drug’s safety and efficacy profile and supporting confidence in its hematology franchise.
• Positive Sentiment: AbbVie and Genmab’s lymphoma program met its primary endpoint in a Phase 3 trial, raising the odds of label expansion and a larger commercial opportunity for Epkinly.
• Positive Sentiment: News that AbbVie is acquiring Apogee Therapeutics has been viewed as a growth-supportive move, signaling continued pipeline expansion through M&A.
• Positive Sentiment: AbbVie also highlighted Aquipta’s efficacy for acute migraine following EU approval, adding another potential growth driver in its neuroscience portfolio.
• Neutral Sentiment: Analysts at Erste Group trimmed their FY2026 and FY2027 EPS estimates slightly, but the reductions were small and remained near consensus, so the impact looks limited.
• Negative Sentiment: US lawmakers opened an investigation into AbbVie and other drugmakers over clinical trials conducted in China, which could create headline risk and raise compliance concerns.

AbbVie Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.